TATE.L | Ticker Profile - Titan Protect

TATE.L

Tate & Lyle plc

Consumer Defensive · Packaged Foods · LSE

$562.25

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.2B

Total market value of the company

Trailing P/E

22.91

Premium valuation

Forward P/E

11.16

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

4.8%

How much profit the company keeps from each dollar of revenue

ROE

6.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$536.00

-5% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 12 analysts covering this stock

About Tate & Lyle plc

Tate & Lyle plc, together with its subsidiaries, engages in the provision of ingredients and solutions to the food, beverages, and other industries in North America, Asia, Middle East, Africa, Latin America, and Europe. The company operates through four segments: Food & Beverage Solutions, Sucralose, Primary Products Europe, and CP Kelco. Its portfolio includes sweeteners, fibres, stabilisers and functional systems, hydrocolloids, and starches, proteins, and functional flours. The company's products are used in beverages, dairy, soups, sauces and dressings, bakery and snacks, confectionery, household, clinical nutrition, industrial, meat and seafood, and personal care applications. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.

https://www.tateandlyle.com

Country: United Kingdom Employees: 5,000 Industry: Packaged Foods

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.214

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0553

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.263

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-15.6%

Historical annualised return based on price data

Max Drawdown

-59.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.28

Very low correlation to market moves

52W High

$580.00

3% below the year high

52W Low

$319.40

76% above the year low

Avg Volume

2,294,030

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

393.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.22

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

80.98

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.71

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.54

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

14.5%

Profit from core operations before interest and tax

Free Cash Flow

$189M

Positive — the business generates more cash than it spends

Revenue (TTM)

$2.0B

Total revenue over the last 12 months

Net Income

$97M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$632.00

Target Median

$536.00

Target Low

$375.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go